![Anti-BOB.1 antibody [SP92] (STJ16101452)](https://cdn11.bigcommerce.com/s-zso2xnchw9/images/stencil/124x110/products/151958/347004/STJ16101452_1__94461.1681999251.jpg?c=1 "Anti-BOB.1 antibody [SP92] (STJ16101452)")
![Anti-BOB.1 antibody [SP92] (STJ16101452)](https://cdn11.bigcommerce.com/s-zso2xnchw9/images/stencil/1280x1280/products/151958/347004/STJ16101452_1__94461.1681999251.jpg?c=1 "Anti-BOB.1 antibody [SP92] (STJ16101452)")
Anti-BOB.1 antibody [SP92] (STJ16101452)
SPECIFICATIONS
ClonalityMonoclonal
HostRabbit
ConjugationUnconjugated
IsotypeIgG1
General Information
| Short Description | Rabbit monoclonal anti-BOB.1 for use in IHC-P in Human samples. Datasheet included with dilution recommendations, and related reagents. |
| Applications | IHC-P |
| Host | Rabbit |
| Reactivity | Human |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Clonality | Monoclonal |
| Clone ID | SP92 |
| Isotype | IgG1 |
| Conjugation | Unconjugated |
| Dilution Range | IHC-P 1:100-1:500 |
| Formulation | Tris Buffer, pH 7.3-7.7, containing 1% BSA and <0.1% Sodium Azide |
| Storage Instruction | Store at 2-8°C for up to 1-year, upon receipt. |
Target Information
Additional Info
| Background | Oct-binding factor-1 (OBF1) , also known as BOB.1, is a B-cell-specific coactivator which has been mapped to chromosome 11q23. Expression of BOB.1/OBF.1 is restricted largely to mature B-cells, with germinal center B-cells normally staining for BOB.1.2, 3 Analyses of BOB.1/OBF.1 expression in a variety of established B-cell lines representing different stages of B-cell development has suggested a constitutive, B-cell-specific expression pattern. LP cells in nodular lymphocyte predominant Hodgkin lymphoma, because they are germinal center-derived, are consistently immunoreactive for BOB.1. Conversely, only some cases of classical Hodgkin lymphoma show BOB.1 immunoreactivity within the Hodgkin and Reed-Sternberg cells. Expression of BOB.1/OBF.1 has been reported in follicular center cell lymphoma, diffuse large B-cell lymphoma and some cases of acute myeloid leukemia. B-CLL, marginal zone lymphoma, and mantle cell lymphoma may show weak to moderate immunoreactivity. |
Information sourced from Uniprot.org